Showing 2751-2760 of 5771 results for "".
- Feliqs Secures $9 Million Series A to Advance FLQ-101 Clinical Trial for Retinopathy of Prematurityhttps://modernod.com/news/feliqs-secures-9-million-series-a-to-advance-flq-101-clinical-trial-for-retinopathy-of-prematurity/2482869/Feliqs Corp. announced the successful completion of a $9 million Series A financing round to advance the company's lead investigational therapy, FLQ-101, into clinical development. Designed as a once-daily oral or intravenous formulation, FLQ-101 aims
- Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd/2482864/Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025
- Opus Genetics' Presbyopia Drop Meets Primary Endpoint in VEGA-3 Phase 3 Trialhttps://modernod.com/news/opus-genetics-announces-vega-3-phase-3-trial-met-primary-endpoint-for-phentolamine-ophthalmic-solution-075-for-the-treatment-of-presbyopia/2482863/Opus Genetics announced positive topline results from VEGA-3, its second pivotal phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with phe
- ForSight Robotics Secures $125 Million in Series B Fundinghttps://modernod.com/news/forsight-robotics-secures-125-million-in-series-b-funding-addressing-global-surgeon-shortage-and-demand-for-ophthalmic-surgery/2482862/ForSight Robotics announced it has completed a $125M Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, incr
- Valorum Biologics Becomes Commercialization Partner for Formycon’s Eylea Biosimilar FYB203/Ahzantive in the US and Canadahttps://modernod.com/news/valorum-biologics-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203ahzantive-aflibercept-mrbb-in-the-united-states-and-canada/2482861/Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the comme
- Hadley and Notal Vision Partner to Empower Patients With Vision Loss Through Education and Leading Technologyhttps://modernod.com/news/hadley-and-notal-vision-partner-to-empower-patients-with-vision-loss-through-education-and-leading-technology/2482860/Hadley and Notal Vision announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision’s ForeseeHome and SCANLY Ho
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- Alcon Introduces Clareon PanOptix Pro in Canadahttps://modernod.com/news/alcon-introduces-clareon-panoptix-pro-in-canada/2482857/Alcon announced the approval of Clareon PanOptix Pro IOL in Canada. According to Alcon, PanOptix Pro leverages the company's proprietary 'ENLIGHTEN NXT' optical technology, which delivers the lowest light scatter and highest reported light utilization of
- New York Eye and Ear Infirmary of Mount Sinai Opens First Comprehensive Center for Refractive Solutions in New Yorkhttps://modernod.com/news/new-york-eye-and-ear-infirmary-of-mount-sinai-opens-first-comprehensive-center-for-refractive-solutions-in-new-york/2482855/The New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the launch of the Center for Refractive Solutions, a facility dedicated to comprehensive vision correction services. Located at 310 East 14th Street in Lower Manhattan, the newly renovated